Gilead and Merck end Trodelvy-Keytruda lung cancer trial

On Monday, Gilead Sciences Inc. GILD and Merck & Co. Inc. MRK on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial ...

‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...
Morningstar

An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...
The New York Times

A New Shot for Cancer Is Convenient, but Poised to Keep Prices High

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
FiercePharma

Merck's partner Kelun touts phase 3 win for ADC-Keytruda combo in first-line lung cancer

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
Seeking Alpha

Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the U.S. drugmaker’s anti-PD-1 therapy in a ...